We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




IMRT Causes Fewer Bowel and Bladder Problems in Women

By MedImaging International staff writers
Posted on 20 Oct 2016
Print article
Image: According to a new study, women with cervical and endometrial cancer have fewer gastrointestinal (GI) and genitourinary (GU) side effects when treated with intensity-modulated radiation therapy (IMRT) (Photo courtesy of ASTRO).
Image: According to a new study, women with cervical and endometrial cancer have fewer gastrointestinal (GI) and genitourinary (GU) side effects when treated with intensity-modulated radiation therapy (IMRT) (Photo courtesy of ASTRO).
Researchers at Yonsei University (Seoul, South Korea), the University of Texas MD Anderson Cancer Center (Houston, USA), and other institutions conducted a multi-center, international study to assess the impact of IMRT, as compared to standard four-field radiation therapy (RT), in 278 patients with cervical or endometrial cancer who received pelvic RT post-operatively at cancer centers in the United States, Canada, Japan, and Korea. Patients were randomly assigned to receive standard RT or IMRT.

The patients were evaluated during the RT treatments via multiple patient questionnaires in order to determine acute toxicities in the GI and GU systems, as well as patient quality-of-life (QOL). The patients were stratified based upon RT dose (45 Gy or 50.4 Gy), use of chemotherapy (no chemotherapy or five cycles of weekly cisplatin at 40 mg/m2), and disease site. The researchers then compared changes in average scores on the questionnaires from baseline to five weeks following RT start, using two-way t-tests.

The results showed that women in the IMRT arm experienced significantly fewer bowel-related toxicity than patients who received standard RT, as indicated by smaller average declines in their Expanded Prostate Cancer Index Composite (EPIC) bowel domain scores. Analysis of sub-scales within the EPIC determined that IMRT patients experienced less severe declines in bowel function, but not bowel bother. IMRT patients also experienced fewer high-level adverse events following treatment, including diarrhea.

Urinary side effects at five weeks from treatment were less prevalent among patients who received IMRT, as indicated by significantly smaller declines in average EPIC urinary domain scores for the IMRT arm. Furthermore, outcome index scores demonstrated fewer declines in health-related QOL following IMRT compared to standard RT. Patients treated with IMRT also had less change in physical wellbeing and additional concerns. The study was presented at the annual meeting of the American Society for Radiation Oncology (ASTRO), held during September 2016 in Boston (MA, USA).

“Many radiation oncologists already use IMRT for women undergoing pelvic radiation, but this research provides data that using IMRT, which is a more resource-intensive treatment, makes a real difference to patients receiving radiation therapy to the pelvic area,” said lead author professor Ann Klopp, MD, PhD, of the MD Anderson Cancer Center. “When performed by an experienced radiation oncology team, IMRT reduces the risk of short-term bowel and bladder side effects for patients with endometrial and cervical cancer.”

IMRT uses advanced technology to manipulate photon and proton beams so that they conform to the shape of a tumor. The radiation intensity of each beam is controlled, and the beam shape changes throughout each treatment, with the goal of adapting the radiation dose to the target and to avoid or reduce exposure of healthy tissue in order to limit the side effects of treatment.

Related Links:
Yonsei University
University of Texas MD Anderson Cancer Center
Gold Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
New
Ultrasound Software
UltraExtend NX
New
DR Flat Panel Detector
1500L
New
Ultrasound Doppler System
Doppler BT-200

Print article

Channels

Radiography

view channel
:	Image: The AI model could be a valuable adjunct to human radiologists in breast cancer diagnoses and risk prediction (Photo courtesy of 123RF)

AI Model Predicts 5-Year Breast Cancer Risk from Mammograms

Approximately 13% of U.S. women, or one in every eight, are predicted to develop invasive breast cancer over their lifetime, with 1 in 39 women (3%) succumbing to the illness, according to the American... Read more

General/Advanced Imaging

view channel
Image: The CIARTIC Move self-driving mobile C-arm has received FDA clearance (Photo courtesy of Siemens)

Self-Driving Mobile C-Arm Reduces Imaging Time during Surgery

Intraoperative imaging faces significant challenges due to staff shortages and the high demands placed on surgical teams in the operating room (OR). A common challenge during many OR procedures is the... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more

Industry News

view channel
Image: Samsung Medison CEO Mr. Yongkwan Kim and Bracco Imaging CEO Dr. Fulvio Renoldi Bracco endorsed a MoU agreement (Photo courtesy of Bracco Group)

Samsung and Bracco Enter Into New Diagnostic Ultrasound Technology Agreement

Samsung Medison (Seoul, South Korea) and Bracco Imaging (Milan, Italy) have entered into a Memorandum of Understanding (MoU) agreement to pioneer a new area for diagnostic ultrasound devices and contrast agents.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.